Assistant Professor, Internal Medicine, Mayo Medical School
Hematology
Dr. Suzanne R. Hayman, MD
|
|
Give Review
Suzanne Hayman practices Hematology. She graduated from Icahn School of Medicine at Mount Sinai. Icahn School of Medicine at Mount Sinai is ranked 20/62 in Research/PrimaryCare. Doctor Suzanne R. Hayman, MD has written publications. She has 88 publications published with PubMed. The lastest publication is: 'Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma.' She is registered with Medicare and accepts Medicare payments.
Publications
- Outcomes of primary refractory multiple Myeloma and the impact of novel therapies.
- Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple Myeloma.
- Soluble suppression of tumorigenicity 2 (sST2), but not Galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and Tropo...
- Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis.
- Multiple Myeloma after kidney transplantation.
- Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias.
- Long-term outcome of patients with multiple Myeloma-related advanced renal failure following auto-SCT.
- Methodological differences account for inconsistencies in reported free VEGF concentrations in pregnant rats.
- Trends in survival of patients with primary plasma cell Leukemia: a population based analysis.
- High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis.
- Long-term Disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy.
- Domino liver transplantation as a cause of acquired familial amyloid polyneuropathy.
- Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant.
- Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple Myeloma following lenalidomide-based initial therapy.
- Continued improvement in survival in multiple Myeloma: changes in early mortality and outcomes in older patients.
- Smoldering multiple Myeloma requiring treatment: time for a new definition?
- Low Levels of Interleukin-1 Receptor Antagonist (IL-1RA) Predict EnGraftment Syndrome after Autologous Stem Cell Transplantation in POEMS Syndrome and Other Plasma Cel...
- Incidence of Supraventricular Arrhythmias during Autologous Peripheral Blood Stem Cell Transplantation.
- Implications of continued response after autologous stem cell transplantation for multiple Myeloma.
- A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?
- Podocyturia predates proteinuria and clinical features of preeclampsia: longitudinal prospective study.
- Outcomes of patients with POEMS syndrome treated initially with radiation.
- Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple Myeloma.
- Management of newly diagnosed symptomatic multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.
- Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myelom...
- Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis.
- Second auto-SCT for treatment of relapsed multiple Myeloma.
- Systemic amyloidosis associated with chronic lymphocytic Leukemia/small lymphocytic lymphoma.
- Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.
- A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple Myeloma.
- Urinary Albumin Excretion Patterns of Patients with Cast Nephropathy and Other Monoclonal Gammopathy-Related Kidney Diseases.
- Trends and outcomes of modern staging of solitary plasmacytoma of bone.
- Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis.
- Trisomies in multiple Myeloma: impact on survival in patients with high-risk cytogenetics.
- High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.
- Immunoglobulin D amyloidosis: a distinct entity.
- Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis.
- Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple Myeloma.
- The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome.
- Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple Myeloma.
- Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory Disease.
- Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple Myeloma.
- Treatment of immunoglobulin light chain (primary or AL) amyloidosis.
- Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple Myeloma: Results from a phase 2 trial.
- Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis.
- IgM Amyloidosis: Clinical Features in Therapeutic Outcomes.
- Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score.
- Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.
- Primary systemic amyloidosis presenting with asymmetric multiple mononeuropathies.
- Diagnosis and management of Waldenström Macroglobulinemia: Mayo stratification of Macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
- Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into Disease biology in patients with POEMS syndrome.
- A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple Myeloma.
- Stem cell transplantation in multiple Myeloma: impact of response failure with thalidomide or lenalidomide induction.
- Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple Myeloma.
- Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple Myeloma: a comparative analysis of 411 patients.
- Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
- Management of newly diagnosed symptomatic multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.
- Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple Myeloma.
- Impact of risk stratification on outcome among patients with multiple Myeloma receiving initial therapy with lenalidomide and dexamethasone.
- Doppler myocardial imaging compared to standard two-dimensional and Doppler echocardiography for assessment of diastolic function in patients with systemic amyloidosis.
- Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.
- Transplantation for IgM amyloidosis and IgM Myeloma.
- Induction of a Chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the...
- A novel report of cig-FISH and cytogenetics in POEMS syndrome.
- Autologous stem cell transplant in 716 patients with multiple Myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisc...
- Autologous stem cell transplantation in patients of 70 years and older with multiple Myeloma: Results from a matched pair analysis.
- Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.
- Serum uric acid: novel prognostic factor in primary systemic amyloidosis.
- Improved survival in multiple Myeloma and the impact of novel therapies.
- Relationship between depth of response and outcome in multiple Myeloma.
- Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed Myeloma.
- Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation.
- Transplantation for amyloidosis.
- Treatment of newly diagnosed multiple Myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement.
- The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.
- Mayo clinic consensus statement for the use of bisphosphonates in multiple Myeloma.
- Clinical implication of centrosome amplification in plasma cell neoplasm.
- Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.
- Flow cytometric detection of circulating Myeloma cells before transplantation in patients with multiple Myeloma: a simple risk stratification system.
- Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed Myeloma.
- Amyloidosis: diagnosis and management.
- Incidence and prognosis of Acute heart failure in the thrombotic microangiopathies.
- Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis.
- Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple Myeloma.
- Improvement in renal function and its impact on survival in patients with newly diagnosed multiple Myeloma.
- Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple Myeloma who are not candidates for stem cell transpla...
- Occurrence and prognostic significance of cytogenetic evolution in patients with multiple Myeloma.
Schools
Mount Sinai School Of Medicine Of New York University
Barnes Jewish Hospital
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- Acute Leukemia
- Anemia
- Chronic Myeloid Leukemia (CML)
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Mayo School of Graduate Medical Education -
Washington University - Barnes-Jewish Hospital -
Icahn School of Medicine at Mount Sinai
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1982684973 | |
| NPPES Provider LastName | HAYMAN | |
| NPPES Provider FirstName | SUZANNE | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 222.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 11.0 | |
| Percent Opioid Claims | 4.95 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1982684973 |
| Last Name Of The Provider | HAYMAN |
| First Name Of The Provider | SUZANNE |
| View All |
Similar Doctors
|
|
Dr. Shernan G. Holtan, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Clive S. Zent, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven I. Robinson, MD |
|
|
Dr. Aneel A. Ashrani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Neil E. Kay, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. David P. Steensma, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cynthia J. Wetmore, MD |
|
|
Dr. Amie E. Jackson, MD |